Hong Kong's regulatory reforms mostly welcomed by pharma
This article was originally published in Scrip
The pharmaceutical industry in Hong Kong has generally welcomed a set of far-reaching recommendations to come out of an official review of pharmaceutical regulation in the territory, although it has lingering concerns about their full implementation.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.